Polymyositis: its presentation, morbidity and mortality

Area of Science:

• Neurology
• Rheumatology
• Immunology

Background:

• Polymyositis is an idiopathic inflammatory myopathy characterized by symmetrical proximal muscle weakness.
• Accurate diagnosis relies on a combination of clinical, electrophysiological, and pathological findings.
• Understanding the natural history and prognostic factors is crucial for effective management.

Purpose of the Study:

• To analyze the clinical features, diagnostic criteria, and prognostic factors in a cohort of polymyositis patients.
• To evaluate the long-term outcomes and response to corticosteroid therapy in polymyositis.
• To classify polymyositis cases and assess the impact of associated conditions like carcinoma.

Main Methods:

• Retrospective analysis of 118 patients diagnosed with polymyositis based on defined criteria over twenty years.
• Inclusion criteria involved clinical, electrophysiological (EMG), and pathological (muscle biopsy) assessments.
• A subgroup of 25 patients had comprehensive diagnostic data; all patients were followed for varying durations (mean 6 years).

Main Results:

• The majority of patients (89%) received high-dose prednisone, showing significant disability improvement within three years.
• Elevated serum creatine kinase (CK) was observed in 64% of cases; EMG was characteristic in 45%.
• 66% of long-term survivors had no functional disability, with many showing disease remission; 33% had persistent disability.

Conclusions:

• High-dose corticosteroid therapy is effective in improving polymyositis-related disability, with maximum benefit seen within three years.
• A significant proportion of polymyositis patients achieve remission or minimal disability after prolonged treatment.
• Polymyositis management requires a comprehensive approach, considering diagnostic nuances and long-term prognostic factors.